These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11073480)

  • 21. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New substances and dosages for thrombolysis in acute myocardial infarct].
    Zeymer U; Neuhaus KL
    Z Kardiol; 1993; 82 Suppl 2():137-41. PubMed ID: 8328192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
    Smith BJ
    J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy.
    Eikelboom JW; Mehta SR; Pogue J; Yusuf S
    JAMA; 2001 Jan 24-31; 285(4):444-50. PubMed ID: 11242429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM
    J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
    Weaver WD
    Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing errors did not have a major impact on outcome in the NINDS t-PA stroke study.
    Messé SR; Kasner SE; Cucchiara BL; Demchuk A; Tanne D; Ouyang B; Levine SR;
    J Stroke Cerebrovasc Dis; 2011; 20(3):236-40. PubMed ID: 20656508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis.
    Mehta SR; Eikelboom JW; Yusuf S
    Lancet; 2000 Aug; 356(9228):449-54. PubMed ID: 10981887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
    Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
    Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
    Neuhaus KL; von Essen R; Vogt A; Tebbe U; Rustige J; Wagner HJ; Appel KF; Stienen U; König R; Meyer-Sabellek W
    J Am Coll Cardiol; 1994 Jul; 24(1):55-60. PubMed ID: 8006283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.